Register

Hematology

General Rheumatology   

Questions discussed in this category

What is your approach to DVT prophylaxis in patients who require IVIG but are at increased risk for thrombotic events?
E.g., a patient with newly diagnosed CIDP who is wheelchair-bound.
2 Answers available
Do you utilize post-vaccination IgG titers to detect common variable immunodeficiency in patients who are about to start or are actively on B cell depleting therapy?
2 Answers available
What is your approach to evaluation in patients who present with erythromelalgia?
1 Answer available
How would approach the management of a patient with significantly positive anticardiolopin and beta 2 glycoprotein antibodies in the absence of any clotting (including obstetric) history but with significant thrombocytopenia (but no other features of active connective tissue disease)?
1 Answer available
How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?
1 Answer available
What is your approach to management of chronic neutropenia in a patient with Sjogren’s who was recently diagnosed with metastatic endometrial cancer and plans to start chemotherapy?
ANC <500
1 Answer available
How do you approach dosing of anakinra in MAS?
1 Answer available
What is your approach to evaluating a patient with known rheumatologic disease and elevated free kappa:lambda ratio, but no evidence of monoclonal immunoglobulins?
1 Answer available
What would be the main indications for opting for biosimilars over an original biologic, outside of insurance barriers?
Are there any instances where you would prefer a biosimilar rather than the reference product? 
2 Answers available
How do you approach the workup for a patient with persistently elevated inflammatory markers (CRP and ESR) whose history and exam do not point to a clear cause?
4 Answers available
How do you manage a patient with progressive cerebellar ataxia and positive cardiolipin antibodies?
Do you wait 12 weeks for confirmation to begin treatment if patient is declining?
1 Answer available
Do you typically see peripheral neuropathy in patients with castleman syndrome?
2 Answers available
Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?
2 Answers available
How do you interpret elevations in ESR and CRP in the setting of increased BMI?
4 Answers available
Do you discontinue or adjust azathioprine when a patient develops elevated MCV after starting it?
When it seems fairly certain that this is a drug effect is it something that can just be monitored or requires a change in approach?
2 Answers available
What is the appropriate management of arthralgias associated with bosutinib?
1 Answer available
Do you recommend continuous antibiotic prophylaxis for patients on complement inhibitors such as eculizumab?
Do you just use antibiotic prophylaxis if therapy is started prior to meningococcal vaccination?
3 Answers available
When considering the use of DOACs in APLS, does the number of positive APLS antibodies influence your decision?
2 Answers available
In patients who develop a VTE, what conditions do you consider as persistent, provoking risk factors, and at what point are they controlled enough to stop anticoagulation?
I.e., what constitutes well-controlled cancer, IBD, nephrotic syndrome, etc. What other diseases do you put in this category (obesity, autoimmune dise...
1 Answer available
Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?
Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?
1 Answer available
How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?
2 Answers available


Papers discussed in this category

JAMA network open, 2018-11-02
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
Blood Adv,
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.
Annals of the rheumatic diseases, 2019-10
EULAR recommendations for the management of antiphospholipid syndrome in adults.
J Thromb Haemost, 2020 Nov 29
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
Front Cardiovasc Med, 2021 Aug 03
Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines.
Clin Microbiol Infect, 2018 Feb 07
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).
Arthritis & rheumatology (Hoboken, N.J.), 2018-03
The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.
PET Clin, 2020 Feb 11
18F-Fluorodeoxyglucose PET/Computed Tomography in the Diagnosis and Monitoring of Giant Cell Arteritis.
Rheumatology (Oxford), 2022 Jul 22
PET/CT of cranial arteries for a sensitive diagnosis of giant cell arteritis.
Arthritis Care Res (Hoboken), 2017 Dec
Impact of Obesity and Adiposity on Inflammatory Markers in Patients With Rheumatoid Arthritis.
JAMA, 1999 Dec 08
Elevated C-reactive protein levels in overweight and obese adults.
Reumatologia, 2020 Feb 28
The impact of obesity on inflammatory markers used in the assessment of disease activity in rheumatoid arthritis - a cross-sectional study.
Pediatr Blood Cancer, 2021 Oct
Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
Ther Adv Musculoskelet Dis, 2020 Nov 24
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.
Mediterranean journal of rheumatology, 2022 Mar 31
Clinical Phenotype and Mechanisms of Leukopenia/Neutropenia in Patients with Primary Sjögren's Syndrome.
Blood, 2022 Jun 23
Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
Best practice & research. Clinical rheumatology, 2019 Dec 19
Antiphospholipid syndrome.

Related Topics in Hematology

Copyright © 2024 theMednet
All Rights Reserved.